 Robert Kramer
Concepts (429)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Foreign Bodies | 14 | 2025 | 104 | 3.780 |
Why?
| | Endoscopy, Gastrointestinal | 14 | 2025 | 228 | 2.940 |
Why?
| | Esophagoscopy | 10 | 2025 | 209 | 1.920 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 5 | 2024 | 213 | 1.820 |
Why?
| | Esophagus | 10 | 2019 | 255 | 1.640 |
Why?
| | Esophageal Stenosis | 6 | 2019 | 54 | 1.530 |
Why?
| | Electric Power Supplies | 8 | 2025 | 51 | 1.470 |
Why?
| | Dilatation | 3 | 2019 | 67 | 1.260 |
Why?
| | Gastroenterology | 8 | 2023 | 180 | 1.250 |
Why?
| | Gastroesophageal Reflux | 3 | 2023 | 234 | 1.210 |
Why?
| | Methyl Parathion | 6 | 2012 | 6 | 1.060 |
Why?
| | Eosinophilic Esophagitis | 8 | 2019 | 325 | 1.030 |
Why?
| | Amphotericin B | 5 | 2010 | 31 | 1.020 |
Why?
| | Vomiting | 3 | 2024 | 130 | 0.980 |
Why?
| | Insecticides | 5 | 2012 | 38 | 0.970 |
Why?
| | Esophageal Diseases | 2 | 2019 | 28 | 0.970 |
Why?
| | Catheterization | 4 | 2019 | 179 | 0.960 |
Why?
| | Polyenes | 3 | 2010 | 16 | 0.940 |
Why?
| | Superior Mesenteric Artery Syndrome | 1 | 2024 | 6 | 0.890 |
Why?
| | Pediatrics | 8 | 2018 | 1101 | 0.880 |
Why?
| | Patient Positioning | 1 | 2024 | 67 | 0.870 |
Why?
| | Child | 43 | 2025 | 21935 | 0.870 |
Why?
| | Gastrointestinal Diseases | 3 | 2017 | 209 | 0.850 |
Why?
| | Duodenoscopes | 2 | 2022 | 7 | 0.850 |
Why?
| | Gastroenterologists | 1 | 2023 | 18 | 0.830 |
Why?
| | Abdominal Pain | 3 | 2024 | 145 | 0.830 |
Why?
| | Quality Improvement | 6 | 2022 | 1178 | 0.810 |
Why?
| | Obesity, Morbid | 3 | 2023 | 264 | 0.770 |
Why?
| | Clinical Competence | 4 | 2018 | 1118 | 0.740 |
Why?
| | Ketorolac | 1 | 2021 | 20 | 0.730 |
Why?
| | Child, Preschool | 26 | 2025 | 11074 | 0.730 |
Why?
| | Laparoscopy | 2 | 2023 | 466 | 0.730 |
Why?
| | Bariatric Surgery | 2 | 2023 | 217 | 0.720 |
Why?
| | Endoscopy | 4 | 2021 | 318 | 0.700 |
Why?
| | Magnets | 2 | 2018 | 19 | 0.700 |
Why?
| | Postoperative Complications | 7 | 2025 | 2654 | 0.690 |
Why?
| | Intestine, Small | 2 | 2018 | 156 | 0.670 |
Why?
| | Pancreatitis | 1 | 2021 | 134 | 0.670 |
Why?
| | Retrospective Studies | 21 | 2024 | 15657 | 0.670 |
Why?
| | Digestive System | 2 | 2020 | 27 | 0.640 |
Why?
| | Quarantine | 1 | 2020 | 30 | 0.640 |
Why?
| | Colonoscopy | 3 | 2022 | 245 | 0.630 |
Why?
| | Fever | 1 | 2021 | 306 | 0.620 |
Why?
| | Pediatric Obesity | 2 | 2023 | 601 | 0.620 |
Why?
| | Endoscopy, Digestive System | 3 | 2025 | 136 | 0.610 |
Why?
| | Single-Balloon Enteroscopy | 1 | 2018 | 4 | 0.610 |
Why?
| | Anesthesia | 2 | 2024 | 189 | 0.600 |
Why?
| | Antifungal Agents | 3 | 2009 | 136 | 0.600 |
Why?
| | Cardiac Surgical Procedures | 2 | 2022 | 530 | 0.590 |
Why?
| | Capsule Endoscopy | 3 | 2017 | 18 | 0.590 |
Why?
| | Esophageal Fistula | 2 | 2016 | 19 | 0.580 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2025 | 132 | 0.580 |
Why?
| | Bile Duct Diseases | 1 | 2018 | 14 | 0.580 |
Why?
| | Vascular Fistula | 2 | 2016 | 23 | 0.570 |
Why?
| | Self Expandable Metallic Stents | 1 | 2018 | 16 | 0.570 |
Why?
| | Adolescent | 28 | 2025 | 21513 | 0.560 |
Why?
| | Humans | 72 | 2025 | 137585 | 0.560 |
Why?
| | Patient Safety | 2 | 2018 | 314 | 0.530 |
Why?
| | Infant | 17 | 2024 | 9465 | 0.530 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 306 | 0.530 |
Why?
| | Esophageal pH Monitoring | 1 | 2016 | 23 | 0.510 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 815 | 0.510 |
Why?
| | Algorithms | 4 | 2025 | 1704 | 0.500 |
Why?
| | Electric Impedance | 1 | 2016 | 107 | 0.500 |
Why?
| | Stomach | 2 | 2020 | 110 | 0.480 |
Why?
| | Duodenum | 1 | 2014 | 78 | 0.440 |
Why?
| | Chronic Pain | 1 | 2018 | 262 | 0.440 |
Why?
| | Mucous Membrane | 1 | 2014 | 125 | 0.430 |
Why?
| | Female | 44 | 2025 | 73304 | 0.420 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 486 | 0.420 |
Why?
| | Checklist | 1 | 2014 | 93 | 0.420 |
Why?
| | Male | 40 | 2025 | 67762 | 0.410 |
Why?
| | Hospitalization | 2 | 2021 | 2199 | 0.410 |
Why?
| | Cytochrome P-450 Enzyme System | 6 | 2012 | 155 | 0.390 |
Why?
| | Operative Time | 2 | 2024 | 145 | 0.360 |
Why?
| | Eating | 6 | 2021 | 380 | 0.360 |
Why?
| | Zona Glomerulosa | 3 | 2000 | 3 | 0.350 |
Why?
| | Esophageal Motility Disorders | 1 | 2011 | 27 | 0.340 |
Why?
| | Spectrum Analysis, Raman | 1 | 2010 | 41 | 0.340 |
Why?
| | Angiotensin II | 3 | 2000 | 99 | 0.330 |
Why?
| | Salicylic Acid | 1 | 2010 | 10 | 0.330 |
Why?
| | Caustics | 1 | 2010 | 7 | 0.330 |
Why?
| | Artifacts | 1 | 2010 | 129 | 0.330 |
Why?
| | Candida albicans | 2 | 2007 | 54 | 0.330 |
Why?
| | Burns, Chemical | 1 | 2010 | 32 | 0.320 |
Why?
| | Jejunal Diseases | 1 | 2009 | 7 | 0.320 |
Why?
| | Food | 1 | 2011 | 164 | 0.310 |
Why?
| | Dermatologic Agents | 1 | 2010 | 70 | 0.310 |
Why?
| | Drug Contamination | 1 | 2009 | 53 | 0.300 |
Why?
| | Cholinesterase Inhibitors | 4 | 2003 | 30 | 0.300 |
Why?
| | Gastrostomy | 3 | 2018 | 117 | 0.300 |
Why?
| | Fluorescence | 1 | 2009 | 160 | 0.300 |
Why?
| | Hemorrhage | 3 | 2014 | 722 | 0.290 |
Why?
| | Cholinesterases | 3 | 2002 | 10 | 0.290 |
Why?
| | Treatment Outcome | 9 | 2024 | 10811 | 0.290 |
Why?
| | Common Bile Duct | 1 | 2007 | 18 | 0.280 |
Why?
| | Drugs, Generic | 1 | 2007 | 22 | 0.280 |
Why?
| | Candidiasis | 1 | 2007 | 56 | 0.270 |
Why?
| | Aldosterone | 2 | 2000 | 45 | 0.270 |
Why?
| | Creatinine | 2 | 2022 | 499 | 0.270 |
Why?
| | Fluoroscopy | 3 | 2018 | 154 | 0.250 |
Why?
| | Stents | 1 | 2010 | 527 | 0.250 |
Why?
| | Prospective Studies | 6 | 2025 | 7604 | 0.240 |
Why?
| | Calcium | 6 | 2003 | 1199 | 0.230 |
Why?
| | Gastrectomy | 2 | 2023 | 126 | 0.230 |
Why?
| | Prone Position | 1 | 2024 | 30 | 0.230 |
Why?
| | Supine Position | 1 | 2024 | 39 | 0.230 |
Why?
| | Biopsy | 4 | 2019 | 1129 | 0.220 |
Why?
| | Obesity | 3 | 2009 | 2992 | 0.220 |
Why?
| | Learning Curve | 1 | 2024 | 72 | 0.220 |
Why?
| | Vascular System Injuries | 1 | 2025 | 71 | 0.220 |
Why?
| | Nausea | 1 | 2024 | 111 | 0.210 |
Why?
| | Hospitals, Pediatric | 2 | 2021 | 508 | 0.210 |
Why?
| | Anastomotic Leak | 1 | 2023 | 41 | 0.210 |
Why?
| | Syndrome | 1 | 2024 | 358 | 0.210 |
Why?
| | Palliative Care | 1 | 2010 | 758 | 0.210 |
Why?
| | Patient Care Team | 3 | 2018 | 631 | 0.200 |
Why?
| | Rats, Sprague-Dawley | 7 | 2012 | 2486 | 0.200 |
Why?
| | Constriction, Pathologic | 1 | 2023 | 245 | 0.200 |
Why?
| | Rats | 15 | 2012 | 5647 | 0.190 |
Why?
| | Cannabinoids | 1 | 2024 | 161 | 0.190 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2012 | 597 | 0.190 |
Why?
| | Patient Satisfaction | 2 | 2017 | 660 | 0.190 |
Why?
| | Paracentesis | 1 | 2001 | 14 | 0.180 |
Why?
| | Extracellular Space | 2 | 2000 | 119 | 0.180 |
Why?
| | Ascites | 1 | 2001 | 46 | 0.180 |
Why?
| | Marijuana Abuse | 1 | 2024 | 233 | 0.180 |
Why?
| | Perfusion | 1 | 2022 | 213 | 0.180 |
Why?
| | Pancreatic Ducts | 1 | 2021 | 85 | 0.170 |
Why?
| | Cohort Studies | 3 | 2018 | 5742 | 0.170 |
Why?
| | Goals | 1 | 2022 | 170 | 0.170 |
Why?
| | Consensus | 5 | 2022 | 683 | 0.170 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1809 | 0.170 |
Why?
| | Risk Assessment | 3 | 2018 | 3457 | 0.170 |
Why?
| | Cardiopulmonary Bypass | 1 | 2022 | 209 | 0.160 |
Why?
| | Multiple Chemical Sensitivity | 1 | 1999 | 1 | 0.160 |
Why?
| | Equipment Contamination | 1 | 2020 | 67 | 0.160 |
Why?
| | Somatoform Disorders | 1 | 1999 | 38 | 0.160 |
Why?
| | Emergencies | 2 | 2011 | 164 | 0.160 |
Why?
| | Informed Consent | 2 | 2017 | 175 | 0.150 |
Why?
| | Alarmins | 1 | 2019 | 26 | 0.150 |
Why?
| | Alcohols | 1 | 1999 | 27 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 316 | 0.150 |
Why?
| | Kinetics | 5 | 2012 | 1670 | 0.150 |
Why?
| | Adverse Outcome Pathways | 1 | 2018 | 4 | 0.150 |
Why?
| | Tranexamic Acid | 1 | 2019 | 40 | 0.150 |
Why?
| | Disinfection | 1 | 2020 | 124 | 0.150 |
Why?
| | Testosterone | 4 | 2012 | 409 | 0.140 |
Why?
| | Play and Playthings | 1 | 2018 | 33 | 0.140 |
Why?
| | Esophageal Mucosa | 1 | 2018 | 22 | 0.140 |
Why?
| | Epidermolysis Bullosa | 1 | 2018 | 67 | 0.140 |
Why?
| | Virtual Reality | 1 | 2019 | 61 | 0.140 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1483 | 0.140 |
Why?
| | Risk Factors | 2 | 2022 | 10388 | 0.140 |
Why?
| | Seizures | 2 | 1999 | 426 | 0.140 |
Why?
| | Intestinal Mucosa | 2 | 2015 | 623 | 0.130 |
Why?
| | Age Factors | 2 | 2016 | 3295 | 0.130 |
Why?
| | Microsomes, Liver | 5 | 2012 | 86 | 0.130 |
Why?
| | Operating Rooms | 1 | 2018 | 123 | 0.130 |
Why?
| | Intestines | 2 | 2012 | 357 | 0.130 |
Why?
| | Disease Outbreaks | 1 | 2020 | 395 | 0.130 |
Why?
| | Gastritis | 1 | 2017 | 108 | 0.130 |
Why?
| | Enteritis | 1 | 2017 | 103 | 0.130 |
Why?
| | Creatine Kinase, MB Form | 1 | 2015 | 4 | 0.120 |
Why?
| | Animals | 23 | 2019 | 36940 | 0.120 |
Why?
| | Angiography | 1 | 2016 | 207 | 0.120 |
Why?
| | Ischemic Preconditioning | 1 | 2015 | 41 | 0.120 |
Why?
| | Young Adult | 7 | 2025 | 13209 | 0.120 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 34 | 0.120 |
Why?
| | Administration, Cutaneous | 4 | 2003 | 129 | 0.120 |
Why?
| | Eosinophilia | 1 | 2017 | 218 | 0.120 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2010 | 560 | 0.110 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2015 | 135 | 0.110 |
Why?
| | Stomach Diseases | 1 | 2014 | 20 | 0.110 |
Why?
| | Cathartics | 1 | 2014 | 15 | 0.110 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 307 | 0.110 |
Why?
| | Burns | 1 | 2019 | 325 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 806 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5131 | 0.110 |
Why?
| | 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 2 | 2003 | 3 | 0.110 |
Why?
| | Colorado | 1 | 2024 | 4565 | 0.110 |
Why?
| | Time-to-Treatment | 1 | 2016 | 205 | 0.110 |
Why?
| | Androstadienes | 1 | 2014 | 107 | 0.110 |
Why?
| | Linear Models | 1 | 2016 | 849 | 0.110 |
Why?
| | Anus Diseases | 1 | 2013 | 9 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2012 | 1587 | 0.110 |
Why?
| | Diltiazem | 1 | 1993 | 29 | 0.100 |
Why?
| | Drug Resistance | 1 | 2014 | 169 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2018 | 546 | 0.100 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2013 | 14 | 0.100 |
Why?
| | Administration, Oral | 3 | 2014 | 816 | 0.100 |
Why?
| | Failure to Thrive | 1 | 2013 | 29 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2031 | 0.100 |
Why?
| | Mitochondria | 2 | 2019 | 948 | 0.100 |
Why?
| | Fistula | 1 | 2013 | 47 | 0.100 |
Why?
| | Injections, Intravenous | 3 | 2002 | 206 | 0.100 |
Why?
| | Pneumonia | 1 | 2019 | 639 | 0.100 |
Why?
| | Abscess | 1 | 2013 | 75 | 0.100 |
Why?
| | Anal Canal | 1 | 2013 | 97 | 0.100 |
Why?
| | Potassium | 1 | 1993 | 147 | 0.100 |
Why?
| | Intestinal Perforation | 1 | 2012 | 46 | 0.100 |
Why?
| | Time Factors | 4 | 2019 | 6828 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 160 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2017 | 766 | 0.090 |
Why?
| | Hydroxylation | 1 | 2012 | 39 | 0.090 |
Why?
| | Deglutition | 1 | 2012 | 72 | 0.090 |
Why?
| | Preoperative Care | 1 | 2014 | 362 | 0.090 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2012 | 86 | 0.090 |
Why?
| | Sulfur | 1 | 2012 | 58 | 0.090 |
Why?
| | Oxidation-Reduction | 4 | 2012 | 1060 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 345 | 0.090 |
Why?
| | Celiac Disease | 1 | 2014 | 294 | 0.090 |
Why?
| | Monocytes | 2 | 2007 | 563 | 0.090 |
Why?
| | Isoenzymes | 1 | 2012 | 304 | 0.090 |
Why?
| | Registries | 1 | 2019 | 2035 | 0.090 |
Why?
| | Infant, Newborn | 2 | 2020 | 6079 | 0.090 |
Why?
| | Dopamine | 2 | 2003 | 303 | 0.090 |
Why?
| | Spectrophotometry | 2 | 2009 | 61 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 496 | 0.080 |
Why?
| | Enteral Nutrition | 2 | 2010 | 202 | 0.080 |
Why?
| | Triamcinolone | 1 | 2010 | 17 | 0.080 |
Why?
| | Spectrometry, Fluorescence | 1 | 2010 | 168 | 0.080 |
Why?
| | Injections, Intralesional | 1 | 2010 | 34 | 0.080 |
Why?
| | Esophageal Perforation | 1 | 2010 | 15 | 0.080 |
Why?
| | Crohn Disease | 1 | 2013 | 243 | 0.080 |
Why?
| | Epilepsy | 2 | 1998 | 333 | 0.080 |
Why?
| | Colloids | 1 | 2010 | 60 | 0.080 |
Why?
| | Trachea | 1 | 2011 | 237 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1509 | 0.080 |
Why?
| | Incidence | 1 | 2016 | 2804 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2069 | 0.080 |
Why?
| | Prednisolone | 1 | 2009 | 83 | 0.080 |
Why?
| | Poisoning | 1 | 2010 | 120 | 0.070 |
Why?
| | United States | 4 | 2023 | 14841 | 0.070 |
Why?
| | Esophagitis | 1 | 2009 | 67 | 0.070 |
Why?
| | Microbial Sensitivity Tests | 2 | 2007 | 361 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4295 | 0.070 |
Why?
| | Aorta | 1 | 2011 | 417 | 0.070 |
Why?
| | Mass Spectrometry | 1 | 2012 | 739 | 0.070 |
Why?
| | Sex Factors | 3 | 2013 | 2071 | 0.070 |
Why?
| | Liver | 8 | 2014 | 1943 | 0.070 |
Why?
| | Deglutition Disorders | 1 | 2010 | 143 | 0.070 |
Why?
| | Cattle | 3 | 2000 | 984 | 0.070 |
Why?
| | Logistic Models | 1 | 2013 | 2074 | 0.070 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2007 | 60 | 0.070 |
Why?
| | Stimulation, Chemical | 2 | 2000 | 59 | 0.070 |
Why?
| | Receptors, Opioid, kappa | 2 | 2003 | 10 | 0.070 |
Why?
| | Water | 1 | 2010 | 460 | 0.070 |
Why?
| | PC12 Cells | 2 | 2003 | 40 | 0.070 |
Why?
| | Body Weight | 5 | 2006 | 985 | 0.070 |
Why?
| | Status Epilepticus | 1 | 1987 | 50 | 0.070 |
Why?
| | Models, Molecular | 1 | 2012 | 1570 | 0.060 |
Why?
| | Growth Hormone | 2 | 1978 | 101 | 0.060 |
Why?
| | Eosinophils | 1 | 2009 | 332 | 0.060 |
Why?
| | Fatty Liver | 1 | 2009 | 243 | 0.060 |
Why?
| | Short Bowel Syndrome | 1 | 2006 | 26 | 0.060 |
Why?
| | Growth | 1 | 2006 | 60 | 0.060 |
Why?
| | Adult | 11 | 2022 | 37929 | 0.060 |
Why?
| | Equipment Design | 1 | 2007 | 522 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1313 | 0.060 |
Why?
| | Pentoxifylline | 1 | 2005 | 25 | 0.060 |
Why?
| | Metabolic Syndrome | 1 | 2009 | 354 | 0.060 |
Why?
| | Pituitary Gland | 2 | 1975 | 148 | 0.060 |
Why?
| | Proteomics | 1 | 2012 | 1111 | 0.060 |
Why?
| | Brain | 4 | 2003 | 2668 | 0.060 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1272 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 180 | 0.060 |
Why?
| | Dietary Fats | 1 | 2006 | 304 | 0.050 |
Why?
| | Electroencephalography | 3 | 1999 | 423 | 0.050 |
Why?
| | Comorbidity | 1 | 2009 | 1622 | 0.050 |
Why?
| | Cell Line | 2 | 2007 | 2847 | 0.050 |
Why?
| | Paraoxon | 1 | 2003 | 2 | 0.050 |
Why?
| | Acetylcholinesterase | 1 | 2003 | 7 | 0.050 |
Why?
| | Receptors, Muscarinic | 1 | 2003 | 19 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2000 | 4193 | 0.050 |
Why?
| | Estradiol | 2 | 1978 | 521 | 0.050 |
Why?
| | Cell Survival | 2 | 1999 | 1120 | 0.050 |
Why?
| | Naltrexone | 1 | 2003 | 97 | 0.050 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2003 | 125 | 0.050 |
Why?
| | Inflammation | 1 | 2013 | 2837 | 0.050 |
Why?
| | Cecum | 1 | 2022 | 33 | 0.050 |
Why?
| | Drug Administration Routes | 1 | 2002 | 38 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2757 | 0.050 |
Why?
| | Endosonography | 1 | 2023 | 156 | 0.050 |
Why?
| | Mathematics | 1 | 2002 | 103 | 0.050 |
Why?
| | Plasma Volume | 1 | 2001 | 19 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2002 | 332 | 0.050 |
Why?
| | Punctures | 1 | 2001 | 40 | 0.050 |
Why?
| | Area Under Curve | 1 | 2002 | 314 | 0.050 |
Why?
| | Disease Management | 2 | 2019 | 628 | 0.040 |
Why?
| | Pharmaceutical Preparations | 3 | 1978 | 179 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2003 | 1316 | 0.040 |
Why?
| | Behavior | 1 | 2001 | 90 | 0.040 |
Why?
| | Ileum | 1 | 2022 | 119 | 0.040 |
Why?
| | Needles | 1 | 2001 | 59 | 0.040 |
Why?
| | Drainage | 1 | 2001 | 173 | 0.040 |
Why?
| | Anions | 1 | 2000 | 31 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2003 | 2057 | 0.040 |
Why?
| | Delphi Technique | 1 | 2022 | 280 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3566 | 0.040 |
Why?
| | Nasal Provocation Tests | 1 | 1999 | 3 | 0.040 |
Why?
| | Safety | 1 | 2001 | 338 | 0.040 |
Why?
| | Calmodulin | 1 | 1999 | 76 | 0.040 |
Why?
| | Personality Inventory | 1 | 1999 | 139 | 0.040 |
Why?
| | Odorants | 1 | 1999 | 109 | 0.040 |
Why?
| | Administration, Topical | 1 | 2019 | 151 | 0.040 |
Why?
| | Video Recording | 1 | 1999 | 180 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 1999 | 153 | 0.040 |
Why?
| | Adrenal Glands | 2 | 1976 | 78 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 283 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2019 | 200 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2017 | 80 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2607 | 0.030 |
Why?
| | Temporal Lobe | 1 | 1998 | 91 | 0.030 |
Why?
| | Contraindications, Procedure | 1 | 2017 | 11 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 1987 | 2691 | 0.030 |
Why?
| | Cell Division | 1 | 1999 | 794 | 0.030 |
Why?
| | Morphine Derivatives | 2 | 1975 | 17 | 0.030 |
Why?
| | Intracellular Fluid | 2 | 2003 | 27 | 0.030 |
Why?
| | Phenytoin | 1 | 1996 | 21 | 0.030 |
Why?
| | Mice | 2 | 2019 | 17787 | 0.030 |
Why?
| | Castration | 4 | 1978 | 14 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 5778 | 0.030 |
Why?
| | Treatment Refusal | 1 | 2017 | 89 | 0.030 |
Why?
| | North America | 1 | 2017 | 313 | 0.030 |
Why?
| | Prodrugs | 1 | 1996 | 52 | 0.030 |
Why?
| | Heart Valves | 1 | 2015 | 43 | 0.030 |
Why?
| | Steroid Hydroxylases | 1 | 1975 | 22 | 0.030 |
Why?
| | Interleukin-1 | 1 | 1999 | 965 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2015 | 282 | 0.030 |
Why?
| | Mouth | 1 | 2015 | 87 | 0.030 |
Why?
| | Laxatives | 1 | 2014 | 19 | 0.030 |
Why?
| | Phosphorylation | 1 | 1999 | 1759 | 0.030 |
Why?
| | Anticonvulsants | 1 | 1996 | 217 | 0.030 |
Why?
| | Fluticasone | 1 | 2014 | 90 | 0.030 |
Why?
| | Coronary Artery Bypass | 1 | 2015 | 234 | 0.030 |
Why?
| | Pruritus Ani | 1 | 2013 | 2 | 0.030 |
Why?
| | Suppuration | 1 | 2013 | 9 | 0.030 |
Why?
| | Fissure in Ano | 1 | 2013 | 4 | 0.030 |
Why?
| | Remission Induction | 1 | 2014 | 288 | 0.030 |
Why?
| | Reperfusion Injury | 1 | 2015 | 279 | 0.030 |
Why?
| | Hypophysectomy | 4 | 1978 | 15 | 0.030 |
Why?
| | Neodymium | 1 | 2012 | 1 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2014 | 1993 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1999 | 922 | 0.020 |
Why?
| | Organ Size | 5 | 1978 | 477 | 0.020 |
Why?
| | Fecal Incontinence | 1 | 2013 | 86 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 786 | 0.020 |
Why?
| | Drug Interactions | 1 | 1993 | 410 | 0.020 |
Why?
| | Nutrition Assessment | 1 | 2011 | 92 | 0.020 |
Why?
| | Brain Injuries | 1 | 1996 | 494 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 673 | 0.020 |
Why?
| | Dantrolene | 1 | 1988 | 6 | 0.020 |
Why?
| | Gallic Acid | 1 | 1988 | 13 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5757 | 0.020 |
Why?
| | Cytosol | 1 | 1988 | 226 | 0.020 |
Why?
| | Pain | 1 | 2013 | 756 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2015 | 7635 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1774 | 0.020 |
Why?
| | Carbon Radioisotopes | 1 | 2006 | 34 | 0.020 |
Why?
| | Palmitates | 1 | 2006 | 18 | 0.020 |
Why?
| | Breeding | 1 | 2006 | 64 | 0.020 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 59 | 0.020 |
Why?
| | Aniline Hydroxylase | 2 | 1975 | 2 | 0.020 |
Why?
| | Ethylmorphine-N-Demethylase | 2 | 1975 | 2 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 2006 | 102 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2828 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2006 | 155 | 0.010 |
Why?
| | Body Height | 1 | 2006 | 199 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2006 | 416 | 0.010 |
Why?
| | Testis | 2 | 1975 | 151 | 0.010 |
Why?
| | In Vitro Techniques | 3 | 2003 | 1092 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4149 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 2006 | 267 | 0.010 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 1 | 2003 | 19 | 0.010 |
Why?
| | Triglycerides | 1 | 2006 | 524 | 0.010 |
Why?
| | Rabbits | 1 | 2005 | 794 | 0.010 |
Why?
| | Quinuclidinyl Benzilate | 1 | 2003 | 2 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2003 | 40 | 0.010 |
Why?
| | Thymidine | 1 | 2003 | 60 | 0.010 |
Why?
| | Radioligand Assay | 1 | 2003 | 48 | 0.010 |
Why?
| | Tritium | 1 | 2003 | 76 | 0.010 |
Why?
| | Autoradiography | 1 | 2003 | 78 | 0.010 |
Why?
| | Neostriatum | 1 | 2003 | 33 | 0.010 |
Why?
| | Chelating Agents | 1 | 2003 | 75 | 0.010 |
Why?
| | Culture Media | 1 | 2003 | 165 | 0.010 |
Why?
| | Brain Stem | 1 | 2003 | 94 | 0.010 |
Why?
| | Corpus Striatum | 1 | 2003 | 167 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2006 | 635 | 0.010 |
Why?
| | Narcotic Antagonists | 1 | 2003 | 181 | 0.010 |
Why?
| | Thalamus | 1 | 2003 | 107 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2006 | 762 | 0.010 |
Why?
| | Middle Aged | 3 | 2015 | 33479 | 0.010 |
Why?
| | Aniline Compounds | 2 | 1978 | 102 | 0.010 |
Why?
| | Thapsigargin | 1 | 1999 | 20 | 0.010 |
Why?
| | Calcimycin | 1 | 1999 | 49 | 0.010 |
Why?
| | Memory | 1 | 2001 | 248 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2003 | 433 | 0.010 |
Why?
| | Aged | 2 | 2015 | 23961 | 0.010 |
Why?
| | Imidazoles | 1 | 1999 | 238 | 0.010 |
Why?
| | Ethylmorphine | 1 | 1978 | 1 | 0.010 |
Why?
| | Discriminant Analysis | 1 | 1998 | 37 | 0.010 |
Why?
| | Seizures, Febrile | 1 | 1998 | 21 | 0.010 |
Why?
| | Thyroxine | 1 | 1978 | 62 | 0.010 |
Why?
| | Phenotype | 1 | 2006 | 3196 | 0.010 |
Why?
| | Learning | 1 | 2001 | 409 | 0.010 |
Why?
| | Hippocampus | 1 | 2003 | 895 | 0.010 |
Why?
| | Functional Laterality | 1 | 1998 | 223 | 0.010 |
Why?
| | Motor Activity | 1 | 2001 | 718 | 0.010 |
Why?
| | Benzene Derivatives | 1 | 1976 | 10 | 0.010 |
Why?
| | Microsomes | 1 | 1976 | 33 | 0.010 |
Why?
| | Benzene | 1 | 1976 | 18 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2006 | 1724 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 840 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 1996 | 129 | 0.010 |
Why?
| | Naphthalenes | 1 | 1976 | 60 | 0.010 |
Why?
| | Pregnenolone | 1 | 1975 | 3 | 0.010 |
Why?
| | Vitamin A Deficiency | 1 | 1975 | 26 | 0.010 |
Why?
| | Prolactin | 1 | 1975 | 96 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1998 | 611 | 0.010 |
Why?
| | Adrenocorticotropic Hormone | 1 | 1975 | 143 | 0.010 |
Why?
| | Corticosterone | 1 | 1975 | 236 | 0.010 |
Why?
| | Ovary | 1 | 1975 | 221 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1975 | 565 | 0.010 |
Why?
| | Prognosis | 1 | 1998 | 4030 | 0.000 |
Why?
| | Mixed Function Oxygenases | 2 | 1978 | 40 | 0.000 |
Why?
| | Thyroidectomy | 1 | 1978 | 106 | 0.000 |
Why?
| | Guinea Pigs | 1 | 1976 | 158 | 0.000 |
Why?
| | Proteins | 1 | 1975 | 1009 | 0.000 |
Why?
|
|
Kramer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|